Asset
RAXIBACUMAB
Emergent BioSolutions Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02339155 | phase4 | completed | 2015-02-24 | 2017-01-03 | Emergent BioSolutions | Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 125349 | BLA | Emergent Manufacturing Operations Baltimore LLC |
Marketed products (1)
- RAXIBACUMAB